Stocks to sell

Affirm (NASDAQ:AFRM) continues to fly multiple red flags, including a high valuation, very tough competition and a bottom line that may be deteriorating. Additionally, there are multiple signs that the Street is quite bearish on the shares. In light of all of these points, I continue to recommend investors sell AFRM stock. The trailing price-to-sales
0 Comments
With SoFi (NASDAQ:SOFI) likely to continue to be hurt by the Biden administration’s policies on student loans and the company still facing many other tough challenges, I am still recommending that investors sell SOFI stock. As Seeking Alpha columnist Business Quant explained in a recent column on SOFI stock, the moratoriums on student loan payments
0 Comments
Mullen Automotive (MULN) is short on cash and big on promises. Short sellers have targeted the stock with a devastating report. Please don’t waste your money. Source: Ringo Chiu / Shutterstock.com Mullen Automotive (NASDAQ:MULN) has most of the ingredients you look for in a pre-revenue electric vehicle (EV) company. Except for money. Mullen has an
0 Comments
Warner Bros. Discovery (NASDAQ:WBD) has experienced nothing but pain since it completed its merger on April 8. This week has been particularly gruesome for owners of WBD stock. On Tuesday, the company warned about its 2022 profits while also suggesting the integration of WarnerMedia with Discovery Communications wouldn’t go as smoothly as investors would like.
0 Comments
Business travel stocks can’t get enough momentum as travel remains depressed compared to pre-pandemic levels. American Express (AXP): Arguably the company most associated with business travel. Booking Holdings (BKNG): The industry leader when it comes to travel booking websites. Choice Hotels (CHH): Dominant when it comes to mid-level and economy hotel properties in the U.S. Source:
0 Comments
After multiple neurology experts harshly criticized Cassava Sciences’ (NASDAQ:SAVA) main thesis and the integrity of its data, I strongly recommend investors refrain from owning any shares of SAVA stock. In my many years of writing about pharmaceutical companies, I’ve never seen multiple experts criticize a drug maker so harshly. These professionals’ tremendous skepticism towards Cassava
0 Comments
Teladoc (NASDAQ:TDOC) stock slumped by more than 50% after the company’s first-quarter earnings report disappointed. TDOC reported a revenue miss of $3.28 million, caused by an abrupt drawdown in its sales cycle. It seems as though the competitive sphere is heating up in the telehealth space, causing crowdedness in the industry. Teladoc’s return on invested
0 Comments